These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32854260)

  • 21. Natural history and growth kinetics of clear cell renal cell carcinoma in sporadic and von Hippel-Lindau disease.
    Li Z; Zhang J; Zhang L; Yao L; Zhang C; He Z; Li X; Zhou L
    Transl Androl Urol; 2021 Mar; 10(3):1064-1070. PubMed ID: 33850741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma.
    Zhao Z; Chen C; Lin J; Zeng W; Zhao J; Liang Y; Tan Q; Yang C; Li H
    Mol Med Rep; 2016 Sep; 14(3):2785-90. PubMed ID: 27485825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
    Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG
    Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor.
    Zagzag D; Krishnamachary B; Yee H; Okuyama H; Chiriboga L; Ali MA; Melamed J; Semenza GL
    Cancer Res; 2005 Jul; 65(14):6178-88. PubMed ID: 16024619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.
    Kammerer-Jacquet SF; Crouzet L; Brunot A; Dagher J; Pladys A; Edeline J; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Patard JJ; Lespagnol A; Mosser J; Denis M; Messai Y; Gad-Lapiteau S; Chouaib S; Belaud-Rotureau MA; Bensalah K; Rioux-Leclercq N
    Int J Cancer; 2017 Jan; 140(1):142-148. PubMed ID: 27623354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
    Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
    Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Von hippel-lindau disease: a genetic and clinical review.
    Haddad NM; Cavallerano JD; Silva PS
    Semin Ophthalmol; 2013; 28(5-6):377-86. PubMed ID: 24138046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma.
    Salama MF; Carroll B; Adada M; Pulkoski-Gross M; Hannun YA; Obeid LM
    FASEB J; 2015 Jul; 29(7):2803-13. PubMed ID: 25805832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin Induces Different Responses in Clear Cell Renal Cell Carcinoma Caki Cell Lines.
    Pasha M; Sivaraman SK; Frantz R; Agouni A; Munusamy S
    Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30909494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The up-regulation of NDRG1 by HIF counteracts the cancer-promoting effect of HIF in VHL-deficient clear cell renal cell carcinoma.
    Zhang ZY; Zhang SL; Chen HL; Mao YQ; Li ZM; Kong CY; Han B; Zhang J; Chen YH; Xue W; Zhai W; Wang LS
    Cell Prolif; 2020 Jul; 53(7):e12853. PubMed ID: 32537867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.
    Chan CC; Collins AB; Chew EY
    Retina; 2007 Jan; 27(1):1-7. PubMed ID: 17218907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cooperative Blockade of CK2 and ATM Kinases Drives Apoptosis in VHL-Deficient Renal Carcinoma Cells through ROS Overproduction.
    Giacosa S; Pillet C; Séraudie I; Guyon L; Wallez Y; Roelants C; Battail C; Evrard B; Chalmel F; Barette C; Soleilhac E; Fauvarque MO; Franquet Q; Sarrazin C; Peilleron N; Fiard G; Long JA; Descotes JL; Cochet C; Filhol O
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33540838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inactivation of the tumor suppressor gene von Hippel-Lindau (VHL) in granulocytes contributes to development of liver hemangiomas in a mouse model.
    Bader HL; Hsu T
    BMC Cancer; 2016 Oct; 16(1):797. PubMed ID: 27733136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pilot study of dovitinib in patients with von Hippel-Lindau disease.
    Pilié P; Hasanov E; Matin SF; Woodson AHH; Marcott VD; Bird S; Slack RS; Fuller GN; McCutcheon IE; Jonasch E
    Oncotarget; 2018 May; 9(34):23390-23395. PubMed ID: 29805741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mutation of von Hippel-Lindau gene and expression of vascular endothelial growth factor in sporadic clear cell renal cell carcinoma and their relationships to angiogenesis].
    Zhang N; Gong K; Guo HF; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(19):1620-4. PubMed ID: 15569457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.
    Sutphin PD; Chan DA; Li JM; Turcotte S; Krieg AJ; Giaccia AJ
    Cancer Res; 2007 Jun; 67(12):5896-905. PubMed ID: 17575159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
    Xu J; Wang B; Xu Y; Sun L; Tian W; Shukla D; Barod R; Grillari J; Grillari-Voglauer R; Maxwell PH; Esteban MA
    Oncogene; 2012 Feb; 31(8):1065-72. PubMed ID: 21841824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAIX and pax-8 Commonly Immunoreactive in Endolymphatic Sac Tumors: A Clinicopathologic Study of 26 Cases with Differential Considerations for Metastatic Renal Cell Carcinoma in von Hippel-Lindau Patients.
    Thompson LDR; Magliocca KR; Andreasen S; Kiss K; Rooper L; Stelow E; Wenig BM; Bishop JA
    Head Neck Pathol; 2019 Sep; 13(3):355-363. PubMed ID: 30291511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.